Immunome Inc SEC Filings

Globe Life Inc. (GL) Form 4 – insider activity dated 30-31 Jul 2025: Co-Chairman & CEO Frank M. Svoboda exercised two tranches of employee stock options, purchasing 25,000 common shares at an $82.56 strike (total cost ≈ $2.06 m). He immediately sold the same 25,000 shares on the open market in four blocks at blended prices of $141.15-$142.58, generating ≈ $3.54 m gross proceeds.

Net effect: direct ownership ended unchanged at 32,747 shares; indirect holdings remain 134,898 shares (family trust) and 1,939.6 units (401-k). Option inventory declined from 50,000 to 25,000 unexercised options with the 2/28/2026 expiry.

Take-aways for investors: the transactions appear cash-neutral on share count but realise a ~$1.5 m spread for the executive. Although the sales represent a modest fraction of his total economic exposure, they may be interpreted as short-term profit-taking rather than a change in long-term commitment.

Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded “A” (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.

Form 4 filing – Immunome, Inc. (IMNM) discloses that Chief Business Officer Kinney Horn received a new employee stock-option grant for 161,000 shares on 07/29/2025.

• Instrument: Non-qualified employee stock option giving the right to buy common stock at an exercise price of $10.60 per share.
• Vesting: 25 % vests on 07/29/2026; the remaining 75 % vests in equal monthly installments (1⁄36) thereafter, fully vesting by 07/29/2029.
• Expiration: 07/28/2035 (10-year term).
• Post-grant holdings: Horn now beneficially owns 161,000 derivative securities; no common shares were reported in Table I.

No shares were sold or disposed of, so the filing reflects compensation-related equity issuance rather than insider selling. The grant modestly increases the company’s fully-diluted share count and aligns the officer’s incentives with long-term shareholder value.

Form 4 snapshot: On 07/29/2025 Immunome (IMNM) granted Chief Scientific Officer Jack Higgins an employee stock option for 196,000 common shares at a strike price of $10.60. The option expires on 07/28/2035, giving a standard 10-year term.

Vesting schedule: 25 % of the award vests on 07/29/2026; the remaining 75 % vests in equal monthly installments over the next 36 months, completing vesting by mid-2029.

Table I shows no purchases or sales of non-derivative shares, so Higgins’ direct common-stock position is unchanged. After the grant he beneficially owns 196,000 derivative securities, all held directly.

Investor takeaway: The filing records routine executive compensation; no immediate cash outlay occurred and potential dilution is limited to the new option pool.

On 07/29/2025 Immunome, Inc. (IMNM) granted President & CEO Clay B. Siegall a stock option for 800,000 common shares at an exercise price of $10.60, expiring 07/28/2035. No shares were bought or sold; the filing reflects only an incentive award.

The option vests over four years: 25% on 07/29/2026 and the remaining 75% in equal monthly installments (1/36) thereafter. Following the grant, Siegall beneficially owns 800,000 derivative securities and retains no change in non-derivative share ownership. The transaction was reported on a single-person Form 4 and was not made under a 10b5-1 plan.

This award strengthens management equity alignment but represents potential dilution if exercised. No other financial metrics, sales, or purchases were disclosed in the filing.

Chief Legal Officer & General Counsel Sandra G. Stoneman filed an SEC Form 4 showing an option grant covering 190,000 Immunome (IMNM) shares on 07/29/2025 at a strike price of $10.60.

Vesting schedule: 25 % on 07/29/2026; the remaining 75 % vests in 36 equal monthly installments, reaching full vesting on 07/29/2029. The option expires on 07/28/2035. Transaction code “A” confirms this is an award, not an open-market trade, and no common shares were acquired or sold.

Following the grant, the reporting person holds 190,000 derivative securities and no change in direct common-share ownership. The filing represents routine, retention-focused compensation and carries minimal immediate market impact.

The Vanguard Group filed a Schedule 13G disclosing a passive ownership stake in Immunome Inc. (IMNM) as of 30 Jun 2025.

• Beneficial ownership: 4,524,952 common shares, representing 5.2 % of outstanding stock, triggering the 5 % reporting threshold.
• Voting vs. dispositive power: Vanguard holds 0 shares with sole voting power and 89,119 shares with shared voting power. It has 4,353,438 shares with sole dispositive power and 171,514 shares with shared dispositive power, underscoring a largely passive position focused on investment management rather than influence.
• The filer qualifies as an investment adviser (IA) under Rule 13d-1(b)(1)(ii)(E) and certifies the shares were acquired in the ordinary course of business, not to influence control.
• No other persons hold more than 5 % indirectly through Vanguard-managed accounts, and no group or subsidiary disclosure is required.
• Certification signed by Ashley Grim, Head of Global Fund Administration, on 29 Jul 2025.

For investors, the filing signals increasing institutional ownership from a major index manager, which can enhance liquidity and visibility but is not indicative of activist intent.